Pathogenetic bases of the combined use of drugs from the groups of hepatoprotectors and phytosorbents

The combined use of hepatoprotectors and phytosorbents in theory is a promising method of pharmacotherapy of comorbid pathologies, as it creates the possibility of presenting them as the result of an extended search for the most relevant forms of manifestation of metabolic disorders, the results of which made it possible to identify general patterns of development and, accordingly, the main directions for their leveling.
It was revealed that the main pathogenetic trend is the failure of metabolic processes in the gastrointestinal tract, which reduces the efficiency of feeding and causes a decrease or fluctuations in productivity (or product quality), the subsequent accumulation of products of disturbed metabolic processes with toxic properties - the development of a local syndrome of endogenous intoxication, a violation of the processes of cavitary and symbiotic digestion in the gastrointestinal tract, with increased alimentary insufficiency, functional overload of the digestive organs and primarily the liver, imbalance of the microbiota and local barrier mechanisms, generalization of the pathological process in the form of the development of systemic endogenous intoxication with the corresponding toxic depression of immunity, functions of organs and body systems, including including dysfunctions and the development of pathology of the hepatobiliary system, in the form of systemic metabolic disorders with the occurrence of a secondary deficiency of nutrients and biologically active substances, acid disorders butalkaline balance and dystrophic phenomena.
The main purpose of this article is, based on the analysis of literary sources, to identify the pathogenetic basis for the combined use of drugs from the hepatoprotector groups and phytosorbents.
We searched for original studies in the scientific databases PubMed, Elsevier Science (Scopus) and Clarivate Analytics (Web of Science) over the past 20 years to identify the features of the above processes, after which a formalized content analysis of the found publications was carried out.
A better understanding of the various mechanisms involved in pathogenesis involving the liver and intestinal microbiota will contribute to the development of improved pharmacological approaches to the treatment of these pathologies.

1. Латентные нарушения метаболизма и риск развития патологии крови и печени в транзитный период у коров / Ю. Н. Алехин, В. И. Моргунова, Л. Н. Каширина, Ю. Е. Суханова // Ветеринарный фармакологический вестник. – 2019. – № 3 (8). – С. 105-116. – DOI 10.17238/issn2541-8203.2019.3.105.

2. Gut-liver axis modulation in fructose-fed mice: a role for PPAR-alpha and linagliptin / F. M. Silva-Veiga, C. S. Miranda, F. F. Martins [et al.] // Journal of Endocrinology. – 2020. – Vol. 247. – No 1. – P. 11-24. – DOI 10.1530/JOE-20-0139.

3. Woodhouse, C. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis / C. Woodhouse, A. Singanayagam, V. C. Patel // Clinical Medicine, Journal of the Royal College of Physicians of London. – 2020.–Vol. 20.–No 5.–P. 490-500.–DOI10.7861/CLINMED.2020-0676.

4. Beyaz Coşkun, A. Therapeutic modulation methods of gut microbiota and gut-liver axis / A. Beyaz Coşkun, A. G. Sağdiçoğlu Celep // Critical Reviews in Food Science and Nutrition. – 2021. – DOI 10.1080/10408398.2021.1902263.

5. Blesl, A. The gut-liver axis in cholestatic liver diseases / A. Blesl, V. Stadlbauer // Nutrients. – 2021. – Vol. 13. – No 3. – P. 1-32. – DOI 10.3390/nu13031018.

6. Simbrunner, B. Therapeutic aspects of bile acid signalling in the gut-liver axis / B. Simbrunner, M. Trauner, T. Reiberger // Alimentary Pharmacology & Therapeutics. – 2021. – DOI 10.1111/apt.16602.

7. D'mello, C. The gut-liver-brain axis: Dietary and therapeutic interventions / C. D'mello, M. G. Swain // The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes, 2021. – P. 205-236. –DOI 10.1016/B978-0-12-821927-0.00007-3.

8. Gut-liver axis: a new point of attack to treat chronic liver damage? / C. Loguercio, T. De Simone, A. Federico [et al.] // The American Journal of Gastroenterology. – 2002. – Vol. 97. – No 8. – P. 2144-2146.

9. Vajro, P. Microbiota and gut-liver axis: Their influences on obesity and obesityrelated liver disease / P. Vajro, G. Paolella, A. Fasano // Journal of Pediatric Gastroenterology and Nutrition. – 2013. – Vol. 56. – No 5. – P. 461-468. – DOI 10.1097/MPG.0b013e318284abb5. – EDN RJSZZP.

10. Targeting the gut-liver axis in liver disease / R. Wiest, A. Albillos, M. Trauner [et al.] // Journal of Hepatology. – 2017. – Vol. 67. – No 5. – P. 1084-1103. – DOI 10.1016/j.jhep.2017.05.007.

11. Ойноткинова, О. Ш. Дислипидемия и ассоциированные метаболические заболевания / О. Ш. Ойноткинова, Е. И. Дедов // Архивъ внутренней медицины. – 2011. – № 1. – С. 67-73.

12. Ойноткинова, О. Ш. Роль микробиоты кишечника в патогенезе дислипидемии и ассоциированных метаболических нарушений / О. Ш. Ойноткинова, Е. Л. Никонов, И. З. Гиоева // Доказательная гастроэнтерология. – 2017. – Т. 6. – № 2. – С. 29-34. – DOI 10.17116/dokgastro20176229-34.

13. Изучение эффективности применения гепатопротектора "Гептрал" и сорбента "БАУ-А" при отравлении свиней афлатоксином В1 / С. А. Танасева, Э. И. Семенов, А. Р. Валиев [и др.] // Российский журнал Проблемы ветеринарной санитарии, гигиены и экологии. – 2016. – № 3(19). – С. 93 -99.

14. Ponomarev, V. The gut-liver axis in the liver's disease: the pathophysiological basic of dysbiosis and hepatopathy's pharmacorrection / V. Ponomarev, O. Popova // FASEB Journal. – 2022. – Vol. 36. – No S1. – P. 3046. – DOI 10.1096/fasebj.2022.36.S1.R3046. – EDN XYLFUR.

15. Дичева, Д. Т. Патогенетическое и клиническое значение оси "микробиота - кишечник - печень" / Д. Т. Дичева, Д. Н. Андреев // Медицинский совет. – 2022. – Т. 16. – № 7. – С. 69-75. – DOI 10.21518/2079-701X-2022-16-7-69-75. – EDN ZWZGUU.

16. Overview of the microbiota in the gutliver axis in viral B and C hepatitis / M. A. Neag, A. D. Buzoianu, A. O. Mitre, A. Catinean // World Journal of Gastroenterology. – 2021. – Vol. 27. – No 43. – P. 7446-7461. – DOI 10.3748/wjg.v27.i43.7446. – EDN RSMGLF.

17. Imai, J. The pathogenic oral–gut–liver axis: new understandings and clinical implications / J. Imai, S. Kitamoto, N. Kamada // Expert Review of Clinical Immunology. – 2021. – Vol. 17. – No 7. – P. 727-736. – DOI 10.1080/1744666X.2021.1935877. – EDN PFVACI.

18. Simbrunner, B. Therapeutic aspects of bile acid signalling in the gut-liver axis / B. Simbrunner, M. Trauner, T. Reiberger // Alimentary Pharmacology & Therapeutics. – 2021. – DOI 10.1111/apt.16602. – EDN MMGXXD.

19. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? / R. Maslennikov, V. Ivashkin, I. Efremova [et al.] // World Journal of Clinical Cases. – 2021. – Vol. 9. – No 31. – P. 9320-9332. – DOI 10.12998/wjcc.v9.i31.9320. – EDN XFXTME.

20. Trebicka, J. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure / J. Trebicka, T. Reiberger, W. Laleman // Visceral Medicine. – 2018. – Vol. 34. – No 4. – P. 270-275. – DOI 10.1159/000490262. – EDN VHPVRG.

21. Wang, J. Roles of the inflammasome in the gut-liver axis (Review) / J. Wang, R. Dong, S. Zheng // Molecular Medicine Reports. – 2019. – Vol. 19. – No 1. – P. 3-14. – DOI 10.3892/mmr.2018.9679. – EDN MBJXLX.

22. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut-liver axis / P. Vitaglione, I. Mennella, F. De Filippis [et al.] // Journal of Nutritional Science. – 2019. – DOI 10.1017/jns.2019.10. – EDN HPKTQT.

23. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: The Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers / A. Gil-Gómez, M. Romero-Gómez, P. Brescia, M. Rescigno // Seminars in Liver Disease. – 2021. – DOI 10.1055/s-0041-1723752. – EDN RQYPBP.

24. Flaxseed powder attenuates non-alcoholic steatohepatitis via modulation of gut microbiota and bile acid metabolism through gut–liver axis / C. Yang, M. Wan, D. Xu [et al.] // International Journal of Molecular Sciences. – 2021. – Vol. 22. – No 19. – DOI 10.3390/ijms221910858. – EDN POKXMD.

25. Nonalcoholic fatty liver disease (Nafld) as model of gut–liver axis interaction: From pathophysiology to potential target of treatment for personalized therapy / F. Fianchi, A. Liguori, A. Gasbarrini [et al.] // International Journal of Molecular Sciences. – 2021. – Vol. 22. – No 12. – DOI 10.3390/ijms22126485. – EDN LMYCIB.

26. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model / H. Li, L. Chen, Q. Wang [et al.] // Frontiers in Pharmacology. – 2021. – Vol. 12. – No APR. – P. 788558. – DOI 10.3389/fphar.2021.788558. – EDN FEPIYY.

27. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis / R. Maslennikov, V. Ivashkin, I. Efremova [et al.] // World Journal of Gastroenterology. – 2022. – Vol. 28. – No 10. – P. 1067-1077. – DOI 10.3748/wjg.v28.i10.1067. – EDN AYMSGW.

28. Premkumar, M. Cytokine storm of covid-19 and its impact on patients with and without chronic liver disease / M. Premkumar, C. K. Kedarisetty // Journal of Clinical and Translational Hepatology. – 2021. – Vol. 9. – No 2. – P. 256-264. – DOI 10.14218/JCTH.2021.00055. – EDN EALGVP.

29. Moreno-Gonzalez, M. The role of the microbiome in liver cancer / M. MorenoGonzalez, N. Beraza // Cancers. – 2021. – Vol. 13. – No 10. – DOI 10.3390/cancers13102330. – EDN HARUDH.

30. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis / S. Van Der Merwe, S. Chokshi, C. Bernsmeier, A. Albillos // Journal of Hepatology. – 2021. – Vol. 75. – No Suppl. 1. – P. S82-S100. – DOI 10.1016/j.jhep.2020.11.029. – EDN SPPONE.

31. Dempsey, J. L. Microbiome Is a Functional Modifier of P450 Drug Metabolism / J. L. Dempsey, J. Y. Cui // Current Pharmacology Reports. – 2019. – Vol. 5. – No 6. – P. 481-490. – DOI 10.1007/s40495-019-00200-w. – EDN PUYENA.